Chan Brandon Dow, Wong Wing-Yan, Lee Magnolia Muk-Lan, Leung Tsz-Wing, Shum Tan-Yu, Cho William Chi-Shing, Chen Sibao, Tai William Chi-Shing
Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Hong Kong, SAR China.
Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong, SAR China.
Front Pharmacol. 2021 Sep 20;12:738139. doi: 10.3389/fphar.2021.738139. eCollection 2021.
Inflammatory bowel disease (IBD) is an idiopathic inflammatory disease affecting the gastrointestinal tract. IBD is characterized by courses of relapse and remission, and remains incurable. Although multiple factors are related to the pathogenesis of IBD, disruption of intestinal mucosa homeostasis has been proposed to be a major contributor to IBD, and abnormal activation of immune cells is key for initiation of the inflammatory response. Macrophages are the most abundant immune cells in the intestine. Once activated, they are responsible for secretion of pro-inflammatory cytokines and chemokines to attract circulating monocytes to inflammatory sites, exacerbating the inflammatory response, and leading to tissue damage. Therefore, the suppression of activated macrophages, cytokine/chemokine production, and subsequent monocyte chemotaxis possesses great potential for the treatment of IBD. In our study, we have demonstrated the inhibitory effect of total extract (CME) on the activation of NF-κB, STAT3, and MAPK signaling in LPS-stimulated RAW264.7 macrophages. In addition, we identified the significant suppressive effect of CME on CCL8 expression in activated macrophages, which potentially contributed to inhibition of monocyte chemotaxis. In the DSS-induced acute colitis mouse model, we have demonstrated the suppressive effect of CME on intestinal macrophage infiltration and its ameliorative effect in IBD. Altogether, we have provided evidence of the therapeutic effect of CME in IBD and the potential of CME for the treatment of IBD.
炎症性肠病(IBD)是一种影响胃肠道的特发性炎症性疾病。IBD的特点是有复发和缓解过程,且仍然无法治愈。尽管多种因素与IBD的发病机制有关,但肠道黏膜稳态的破坏被认为是IBD的主要促成因素,免疫细胞的异常激活是炎症反应启动的关键。巨噬细胞是肠道中最丰富的免疫细胞。一旦被激活,它们负责分泌促炎细胞因子和趋化因子,以吸引循环中的单核细胞到炎症部位,加剧炎症反应,并导致组织损伤。因此,抑制活化的巨噬细胞、细胞因子/趋化因子的产生以及随后的单核细胞趋化作用在IBD治疗中具有巨大潜力。在我们的研究中,我们已经证明了总提取物(CME)对脂多糖刺激的RAW264.7巨噬细胞中NF-κB、STAT3和MAPK信号通路激活的抑制作用。此外,我们确定了CME对活化巨噬细胞中CCL8表达的显著抑制作用,这可能有助于抑制单核细胞趋化作用。在葡聚糖硫酸钠(DSS)诱导的急性结肠炎小鼠模型中,我们已经证明了CME对肠道巨噬细胞浸润的抑制作用及其对IBD的改善作用。总之,我们提供了CME对IBD治疗作用的证据以及CME治疗IBD的潜力。